Silexion prices $2.5 million public offering, closes it days later

Silexion Therapeutics Corp announced on August 11, 2026 the pricing of a public offering of an aggregate of 3,846,161 of the Company's ordinary shares and series E warrants to purchase up to 3,846,161 ordinary shares at a combined public offering price of $0.65 per share and accompanying warrants.¹ The series E warrants have an exercise price of $0.65 per share, are exercisable immediately upon issuance and expire five years from the date of issuance.¹

Gross proceeds from the offering, before deducting placement agent fees and other offering expenses, were expected to be approximately $2.5 million.¹ H.C. Wainwright & Co. served as exclusive placement agent, per the release.

The offering closed on August 13, 2026. According to the company's 8-K, the closing covered 2,028,619 ordinary shares, 1,817,542 pre-funded warrants, and 3,846,161 Series E ordinary warrants, at a purchase price of $0.65 per share and accompanying ordinary warrants, and $0.6499 per pre-funded warrant and accompanying ordinary warrants.¹ Net proceeds to the Company from the offering were approximately $2.1 million before deducting estimated offering expenses.¹

In connection with the closing, the Company converted $750,001 of principal outstanding under its amended and restated promissory note with Moringa Sponsor into 1,153,848 ordinary shares at a conversion price of $0.65 per share, reducing the amount outstanding under the note to $206,462.¹ Separately, the Company issued an aggregate of 823,770 ordinary shares upon the exercise of pre-funded warrants issued in the offering prior to closing.¹

After these transactions, the Company estimated its shareholders' equity as of June 30, 2026, as adjusted, at approximately $3.2 million,¹ though that estimate is preliminary and has not been audited or reviewed by the Company's independent registered public accounting firm.¹